Immunex Enbrel Sales Capped At $800 Mil. With Current Production Capacity

Sales of Immunex' rheumatoid arthritis drug Enbrel (etanercept) in the U.S. are capped at $800 mil. a year at the current manufacturing capacity, Immunex said in an Aug. 9 Securities & Exchange Commission filing.